Midomafetamine
Phase 3Small molecule
Midomafetamine is a small molecule that works as a Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]
Midomafetamine is one of 10 small molecule programs targeting Central diabetes insipidus. It is currently in Phase 3.
3
Indications
23
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in PTSD
#DrugCompanyPhaseTrials
1Nurtec
PfizerApproved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ritalin
NovartisPhase 2
Midomafetamine
LLykos Therapeutics
Phase 3
Reboxetine
UUniversity of Zurich
Phase 2
Psychedelic
CCanadian Forces Health Services Centre Ottawa
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment6 trials
Show 3 more trials
PTSD5 trials
Dose Optimization of MDMA-Assisted Therapy for PTSD
Recruiting·—·Phase 2·NCT06418178·60 enrolled
Anxiety2 trials
Methamphetamine2 trials
7 more indications
Relapse1 trial
Post-Traumatic Stress Disorder1 trial
Double-blind1 trial
Moderate Hepatic Impairment1 trial
Chronic PTSD1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Midomafetamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLykos Therapeutics